Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the bestdose software

Therapeutic Drug Monitoring

Volumn 38, Issue 3, 2016, Pages 332-342

  Neely, Michael ^a   Philippe, Michael ^b,c,d   Rushing, Teresa ^e   Fu, Xiaowei ^a   Van Guilder, Michael ^a   Bayard, David ^a   Schumitzky, Alan ^a   Bleyzac, Nathalie ^b,c,d   Goutelle, Sylvain ^c,d  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b Institute of Pediatric Hematology and Oncology   (United States)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e Pharmacy Department   (France)

Author keywords

Bayesian; Busulfan; Children; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BUSULFAN; ALKYLATING AGENT;

ADOLESCENT; ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CALCULATION; CHILD; COMPUTER PROGRAM; DRUG EXPOSURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SAMPLING; BAYES THEOREM; BIOLOGICAL MODEL; COMPARATIVE STUDY; DOSE RESPONSE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; PRESCHOOL CHILD; SOFTWARE; STATISTICAL BIAS; VALIDATION STUDY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ALGORITHMS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BAYES THEOREM; BIAS; BUSULFAN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; MODELS, BIOLOGICAL; SOFTWARE; YOUNG ADULT;

EID: 84969894894     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000276     Document Type: Article

References (50)

1. Vassal G, Michel G, Espérou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113-123.
2. Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:307-314.
3. Nguyen L, Fuller D, Lennon S, et al. IV busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transpl. 2004;33:979-987.
4. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharm. 2002;53:386-389.
5. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transpl. 1996;17:225-230.
6. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
7. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transpl. 2002;30:167-173.
8. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transpl. 2001;28:1013-1018.
9. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transpl. 1995;16:31-42.
10. McCune JS, Bemer MJ, Barrett JS, et al. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20:754-763.
11. McCune JS, Baker KS, Blough DK, et al. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol. 2013;53: 264-275.
12. Maheshwari S, Kassim A, Yeh RF, et al. Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transpl. 2013;49:366-369.
13. Phillipe M, Bleyzac N, Goutelle S. Pharmacokinetic, Analytical Issues In busulfan area under the curve estimation and simulation. Biol Blood Marrow Transpl. 2016;22:185.
14. Long-Boyle JR, Savic R, Yan S, et al. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015;37: 236-245.
15. Diestelhorst C, Boos J, McCune JS, et al. Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM model to optimize dosing. Eur J Clin Pharmacol. 2014;70:839-847.
16. Savic RM, Cowan MJ, Dvorak CC, et al. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2013;19:1608-1614.
17. Veal GJ, Nguyen L, Paci A, et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer. 2012;48:3063-3072.
18. Bartelink IH, van Kesteren C, Boelens JJ, et al. Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults. Ther Drug Monit. 2012;34:574-583.
19. Bartelink IH, Boelens JJ, Bredius RGM, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric Haematopoietic stem cell transplantation patients. Clin Pharmacokinet. 2012;51:331-345.
20. Paci A, Vassal G, Moshous D, et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit. 2012;34:198-208.
21. Bleyzac N. The use of pharmacokinetic models in paediatric oncohaematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam Clin Pharmacol. 2008;22:605-608.
22. Neely M, Margol A, Fu X, et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015;59:3090-3097.
23. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian Dose Optimization. J Clin Pharmacol. 2008;48:1081-1091.
24. Jelliffe R, Bayard D, Milman M, et al. Achieving target goals most precisely using nonparametric compartmental models and multiple model design of dosage regimens. Ther Drug Monit. 2000;22:346-353.
25. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new multiple model dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34:57-77.
26. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transpl. 2001;28:743-751.
27. Jelliffe RW. The USCPACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care. 1991;922-924. PMCID: PMC2247677.
28. Peris JE, Latorre JA, Castel V, et al. Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1999;730:33-40.
29. Bleyzac N, Barou P, Aulagner G. Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl. 2000;742:427-432.
30. Reis dos EO, Vianna-Jorge R, Suarez-Kurtz G, Lima ELDS, Azevedo D de A. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19:1666-1674.
31. Yamada WM, Bartroff J, Bayard DS, et al. The Nonparametric Adaptive Grid Algorithm for Population Pharmacokinetic Modeling [Internet]. 2014. Report No.: TR-2014-1. Available at: http://www.lapk.org/techReports.php. Accessed November 1, 2015.
32. Tatarinova T, Neely M, Bartroff J, et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodynam. 2013;40: 189-199.
33. Neely MN, van Guilder MG, Yamada WM, et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467-476.
34. Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25-36.
35. Traub SL, Johnson CE. Comparison of methods of estimating creatinine clearance in children. Am J Hosp Pharm. 1980;37:195-201.
36. Brink ten MH, Zwaveling J, Swen JJ, et al. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19: 1572-1586.
37. Burnham KP, Anderson DR. Model Selection, Multi-Model Inference. New York: Springer; 2010.
38. Bayard DS, Jelliffe RW, Neely MN. Bayes Risk as an Alternative to Fisher Information in Determining Experimental Designs for Nonparametric Models. PODE 2012. Surrey, UK: Windlesham; 2013.
39. Bayard DS, Jelliffe RW, Neely MN. Experiment Design Based on Bayes Risk and Weighted Bayes Risk with Application to Pharmacokinetic Systems. Population Optimum Design of Experiment. Basel, Switzerland: 2014.
40. Goutelle S, Bourguignon L, Maire PH, et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009;53:2974-2981.
41. Bayard DS, Milman MH, Schumitzky A. Design of dosage regimens: a multiple model stochastic control approach. Int J Biomed Comput. 1994;36:103-115.
42. Hope WW, Vanguilder M, Donnelly JP, et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother. 2013;57:1888-1894.
43. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115:4597-4604.
44. Wall DA, Chan KW, Nieder ML, et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;54:291-298.
45. Meibohm B, Laer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7: E475-E487.
46. Dupuis LL, Sibbald C, Schechter T, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transpl. 2008;14:576-582.
47. Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect. 2015;21:886-893.
48. Hennig S, Holthouse F, Staatz CE. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Clin Pharmacokinet. 2015;54:409-421.
49. Zao JH, Schechter T, Liu WJ, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transpl. 2015;21:1471-1478.
50. Aarons L, Ogungbenro K. Optimal design of pharmacokinetic studies. Basic Clin Pharmacol Toxicol. 2010;106:250-255.